Photodynamic therapy (PDT) offers a new approach to selective tumor eradication. Modifications designed to increase and optimize efficacy continue to emerge. Selective photodamage to malignant cells and their environment can bring about tumor cell destruction, shutdown of the tumor vasculature, stimulation of immunologic anti-tumor effects and potentiation of other therapeutic effects. Current development of combination protocols may provide a better rationale for integration of PDT into clinical practice. An example described here is the ability of a sequential (two-sensitizer) PDT protocol to enhance the efficacy of photokilling. The first step involves low-level lysosomal photodamage that has been shown to promote the apoptotic response to subsequent photodynamic effects directed at mitochondria. In this report, we demonstrate the ability of Photofrin, an FDA-approved photosensitizing agent, to serve as either the first or second element of the sequential protocol.

中文翻译：

---

光动力疗法：通过序贯方案提高疗效

光动力疗法 (PDT) 提供了一种选择性根除肿瘤的新方法。旨在提高和优化功效的修改不断出现。对恶性细胞及其环境的选择性光损伤可导致肿瘤细胞破坏、肿瘤脉管系统关闭、免疫抗肿瘤作用的刺激和其他治疗作用的增强。目前开发的联合方案可能为将 PDT 整合到临床实践中提供更好的理由。此处描述的一个示例是顺序（双敏化剂）PDT 协议提高光杀伤效果的能力。第一步涉及低水平的溶酶体光损伤，该损伤已被证明可促进对随后针对线粒体的光动力效应的凋亡反应。在这份报告中，